Dawe Nicholas, Sainsbury David, Veeramani Siva, Ragbir Maniram, Ahmed Omar A
From the Department of Plastic and Reconstructive Surgery, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
Ann Plast Surg. 2015 Jun;74(6):737-42. doi: 10.1097/SAP.0000000000000016.
Merkel cell carcinoma (MCC) is a rare, aggressive skin tumor. Controversies regarding optimal management persist due to inadequate data and knowledge regarding tumor biology. Head and neck MCC increases both oncological and reconstructive challenges, compounded by predominantly elderly patients. We review our practice and outcomes, review evidence, and discuss the difficulties in delivering best practice management.
All patients with primary head and neck MCC, managed by a single multidisciplinary team between January 2001 and December 2010, were identified through retrospective analysis of a pathology coding database. A literature review was performed.
Twenty patients, with a mean age of 83.5 years (40-99 years) and presenting with mean symptom duration of 5 months, had primary tumors involving the nose (n = 2), periorbital region (n = 5), cheek (n = 6), and the temple and scalp (n = 7). Mean tumor size was 2.1 cm (range, 0.5-7.5 cm). Reconstructive techniques were direct closure (n = 8), skin grafting (n = 7), local flaps (n = 4), and free anterolateral thigh flap (n = 1). Two (10%) patients presented with nodal disease. Eight (40%) patients re-presented with nodal recurrence at a mean of 7 months with 6 undergoing salvage neck dissections. Adjuvant radiotherapy was completed in 5 cases, and chemotherapy used for palliation in 1 case. Most of the patients declined radiotherapy due to adverse effects or frailty.
Our series demonstrates the profound challenges in managing head and neck MCC, including tailoring definitive primary treatment and current consensus management to elderly patients. Regional nodal assessment and management remains crucial to achieving this goal.
默克尔细胞癌(MCC)是一种罕见的侵袭性皮肤肿瘤。由于关于肿瘤生物学的数据和知识不足,对于最佳治疗方案仍存在争议。头颈部MCC增加了肿瘤学和重建方面的挑战,且主要发生在老年患者中。我们回顾了我们的治疗实践和结果,审视了证据,并讨论了提供最佳治疗管理的困难。
通过对病理编码数据库进行回顾性分析,确定了2001年1月至2010年12月期间由单一多学科团队管理的所有原发性头颈部MCC患者。进行了文献综述。
20例患者,平均年龄83.5岁(40 - 99岁),平均症状持续时间为5个月,原发性肿瘤累及鼻子(n = 2)、眶周区域(n = 5)、脸颊(n = 6)以及颞部和头皮(n = 7)。平均肿瘤大小为2.1 cm(范围0.5 - 7.5 cm)。重建技术包括直接缝合(n = 8)、植皮(n = 7)、局部皮瓣(n = 4)和游离股前外侧皮瓣(n = 1)。2例(10%)患者出现淋巴结疾病。8例(40%)患者出现淋巴结复发,平均复发时间为7个月,其中6例接受了挽救性颈清扫术。5例患者完成了辅助放疗,1例患者接受了姑息化疗。大多数患者由于不良反应或身体虚弱而拒绝放疗。
我们的系列研究表明,在管理头颈部MCC方面存在巨大挑战,包括为老年患者量身定制明确的原发性治疗和当前的共识治疗方案。区域淋巴结评估和管理对于实现这一目标仍然至关重要。